


EU Biosimilar Guidelines

5th EGA Symposium on biosimilars May 2007 Peter Richardson European Medicines Agency (EMEA)



Current Biosimilar Guidelines – Summary





Current Guidelines – amendment ?

- Experience being gained
- Most discussion on epoetin
 - » Guideline did not address Contra-indication for S/C route for epoetin alfa
 - » Discussion on whether i/v alone can be authorised (risk of off-label s/c use)
 - » Potency assay range (80-125%) puts additional demands on equivalence margins
- Amendment could be considered in medium term



- LMMHs
- Interferon alfa
- Immunogenicity
- Comparability



LMMHs

- » Similar biological medicinal products containing low molecular weight heparins – (Non-)Clinical Issues. CHMP/BMWP/496268/06
- » CONCEPT PAPER released for consultation Jan 2007. Comments by 30 Apr 2007
- » Draft Guideline: release for consultation expected 4Q 2007.



Low Molecular Mass Heparin

Concept Paper

»LMMH fits definition of biological = biosimilar route is appropriate

» Characterisation of complex molecules

» Pharmacokinetic bioequivalence not sufficient



- Interferon alfa
 - » Concept Paper Adopted (consultation concluded August 2006).
 - » Draft Guideline: release for consultation expected 4Q 2007.



Interferon alfa

- Guideline Drafting Ongoing
 - » Non-clinical: Pharmacodynamics / Toxicology
 - » Clinical:
 - PK / PD (any validated markers)
 - Efficacy: most sensitive population (Hep C)
 - Study design / Endpoint / Duration
 - Extrapolation of data / Indications
 - Safety: AE profile / Immunogenicity
 - » Pharmacovigilance: normal requirements



Immunogenicity

- » Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins. CHMP/BMWP/14327/06
- » GUIDELINE released for consultation Jan 2007
- » Comments by 31 July 2007
- » Workshop (Regulators), September 2007.




Immunogenicity

• Guideline applicable to peptides & proteins

- » i.e. innovator and biosimilar medicinal products
- » Risk factors
- » Predicitivity of non-clinical models
- » Assay development
- » Clinical consequences
- » Clinical safety
- » Risk management plan



Comparability / Biosimilar Guideline - Revision





• Comparability

- » Comparability of Biotechnology-Derived Medicinal Products after a change in the Manufacturing Process Non-Clinical and Clinical. CHMP/BMWP/101695/06
- » GUIDELINE released for consultation Jan 2007
- » Comments by 30 Apr 2007

Comparability – changes to process, (Non-)clinical requirements

• Guideline similar to ICH Q5E

- » Risk based approach
- » Sequential: start with quality data
- » Depending on risk / complexity / experience may need to perform additional (non)clinical studies.



Patient Information

Questions and answers

- » What is a biological medicine?
- » What is a biosimilar medicine?
- » How is a biosimilar medicine authorised?
- » How is a biosimilar medicine evaluated?
- » Is the safety of biosimilar medicines monitored?
- Summary of product characteristics
 - » Guideline may consider biosimilars (2008)



Thank you for your attention !

- For your information:
 - » EMEA Website: http://www.emea.europa.eu
 - » Biosimilars:

http://www.emea.europa.eu/htms/human/humanguidelines/multidiscipline.htm

» Peter.Richardson@emea.europa.eu